19Oct 2021
Real‐world use of first‐generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration‐resistant prostate cancer

Real‐world use of first‐generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration‐resistant prostate cancer

To investigate the recent real‐world use of first‐generation antiandrogens (FGAs) in metastatic castration‐resistant prostate cancer (mCRPC) using a retrospective multicentre cohort study. The electronic CRPC Australian Database (ePAD) was interrogated to identify patients with mCRPC. Clinicopathological features, treatment and outcome data, stratified by FGA use, were retrieved and reported through descriptive statistics. Survival analyses were calculated using the Kaplan–Meier method and groups compared using log‐rank tests. Factors influencing overall survival (OS) were analysed using Cox proportional hazards regression model...

  • #urology

Like

Save

Share